Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction

Exclusion Criteria

• •1. Patient in whom oral administration is not possible at the initial stage (e.g., emergency digestive surgery, acute mesenteric ischemia, etc.).
• •2. Patient treated with SGLT2 inhibitor before ICU admission
• •3. Hypoglycemia \< 0.5 g/L (2.75 mmol/L)
• •4. End-stage kidney disease undergoing maintenance dialysis
• •5. Medical history of type 1 diabetes (gliflozins are not authorized for treatment of this type of diabetes)
• •6. Medical history of diabetic ketoacidosis
• •7. Ongoing Fournier's gangrene
• •8. Current treatment with lithium
• •9. Cirrhose child C
• •10. Do not resuscitate order at inclusion in the study
• •11. Concomitant participation in another interventional therapeutic trial
• •12. Patient deprived of liberty or under legal protection (guardianship, conservatorship, or legal protection)
• •13. Pregnancy or breastfeeding
• •14. Contraindications to dapagliflozin